ReviewJournal of medical case reports2021
Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
Review in Journal of medical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis.Frontiers in oncology · 2026Article
- Venetoclax combined with azacitidine for treatment of a blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.Experimental and therapeutic medicine · 2026Article
- Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.Cancer cell international · 2025Article
- Article
- Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma.Annals of hematology · 2025Article
- Imaging findings for 2-[Frontiers in medicine · 2025Article
- Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.Iranian journal of pathology · 2025Article
- Blastic plasmacytoid dendritic cell neoplasm: Two case reports.World journal of clinical oncology · 2024Article
- Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.Annals of hematology · 2024Review
- Review
- Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study.Frontiers in oncology · 2023Article
- Blastic Plasmacytoid Dendritic Cell Neoplasm With Central Nervous System Involvement: A Case Report.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting. CASE PRESENTATION: A 54-year-old Caucasian male was referred to the Haematology Unit with an enlarged inguinal lymph node which was diagnostic of a blastic plasmacytoid dendritic cell neoplasm. The staging revealed disseminated disease (skin, visceral, lymph nodes, and bone marrow). He received chemotherapy with an acute myeloid leukaemia-like regime. Afterwards, he underwent allogeneic haematopoietic stem cell transplantation, though it was not successful, showing a relapse 14 months later with hepatic and central nervous system dissemination. Intrathecal chemotherapy was administered, and venetoclax (anti-bcl2 agent) was started in an off-label indication based on most recent literature. The disease halted its course for 3 months. In the end, the patient's disease progressed and so he succumbed due to infectious complications.
conclusionsVenetoclax monotherapy seems not enough to control the disease progression under CNS involvement and other treatments should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.